Last updated on June 2019

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Clinical Study Identifier: NCT03430843

Find a site near you

Start Over

St. Joseph Heritage Healthcare

Fullerton, CA United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

San Antonio Military Medical Center

Fort Sam Houston, TX United States
  Connect »

Millennium Oncology

Houston, TX United States
  Connect »

UZ Antwerpen

Antwerp, Belgium
  Connect »

Irccs Irst

Meldola, Italy
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Imperial NHS Trust

London, United Kingdom
  Connect »

Mount Vernon Cancer Centre

Northwood, United Kingdom
  Connect »

CHRU Besan on

Besançon, France
  Connect »

ICM Val d'Aurelle

Montpellier, France
  Connect »

CHRU Besan on

Besançon, France
  Connect »

CHRU Besan on

Besançon, France
  Connect »

CHRU Besan on

Besançon, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.